Correction to: Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals by Liz Morrell, Sarah Wordsworth, Anna Schuh, Mark R. Middleton, Sian Rees, Richard W. Barker

Get full text

Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in a... by Elena Elez, Antonio Cubillo, Pilar Garcia Alfonso, Mark R. Middleton, Ian Chau, Baha Alkuzweny, Ann Alcasid, Xiaosong Zhang, Eric Van Cutsem

Get full text

712 IMPORT-201 (IMP-MEL): a phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist (PORT-2) and pembrolizumab for advanced melanoma and non-small cell... by David Thompson, Mark R Middleton, David J Pinato, Ian Walters, Robert Krämer, Uzi Gileadi, Nicholas Coupe, Justin Fairchild, Russell Poe, Carri Browne, Steven Innaimo, Carmela De Santo

Tissue-resident natural killer cells support survival in pancreatic cancer through promotion of cDC1-CD8 T activity by Simei Go, Constantinos Demetriou, Giampiero Valenzano, Sophie Hughes, Simone Lanfredini, Helen Ferry, Edward Arbe-Barnes, Shivan Sivakumar, Rachel Bashford-Rogers, Mark R Middleton, Somnath Mukherjee, Jennifer Morton, Keaton Jones, Eric O Neill

Get full text

Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-labe... by Mark R Middleton, Winald R Gerritsen, Ian Walters, Licia Rivoltini, Niven Mehra, Jeroen H A Creemers, Carl G Figdor, I Jolanda M de Vries, Uzi Gileadi, Inka Pawlitzky, Konstantina Grosios, Petronella B Ottevanger

Get full text

PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent non‐muscle‐invasive bladder cancer by Victoria K. Woodcock, Ji‐Li Chen, Karin Purshouse, Chrissie Butcher, Linda Collins, Caroline Haddon, Gillian Verrall, Leena Elhussein, Corran Roberts, Andrea Tarlton, Margarida Rei, Giorgio Napolitani, Mariolina Salio, Mark R. Middleton, Vincenzo Cerundolo, Jeremy Crew, Andrew S. Protheroe

Get full text

Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study by Jessica C Hassel, Mark R Middleton, Alexander N Shoushtari, Omid Hamid, Paolo A Ascierto, Todd M Bauer, John M Kirkwood, Friedegund Meier, Marlana Orloff, Paul C Lorigan, Chris Holland, Cornelia Mauch, Ramakrishna Edukulla, April K S Salama, Thomas R Jeffry Evans, Shaad E Abedin

Get full text

Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination by Brian Shine, Robert Pell, Weiyu Ye, Mark R Middleton, Tim James, Stephanie Jones, Robert A Watson, Ian S D Roberts, Monika Hofer, Damian Jenkins, Miranda J Payne, Nicholas Coupe, Chelsea A Taylor, Elsita Jungkurth, Rosalin Cooper, Orion Tong, Eleni Ieremia, David Maldonado-Perez, Benjamin P Fairfax

Get full text

705 Biodistribution and shedding analysis following RP1 oncolytic immunotherapy dosing in patients from the IGNYTE clinical trial by Dirk Schadendorf, Gino K In, Mark R Middleton, Mohammed Milhem, Adel Samson, Bartosz Chmielowski, Michael K Wong, Robert S Coffin, Trisha M Wise-Draper, Eva Muñoz-Couselo, Joseph J Sacco, Georgia M Beasley, Judith Michels, Praveen K Bommareddy, Katy K Tsai, Jeannie W Hou, Alina Monteagudo, Tawnya Lynn Bowles, Ari M VanderWalde, Jason Alan Chesney, Fade Mahmoud, Walter Hong, Aaron Clack

Author Correction: Tumour gene expression signature in primary melanoma predicts long-term outcomes by Manik Garg, Dominique-Laurent Couturier, Jérémie Nsengimana, Nuno A. Fonseca, Matthew Wongchenko, Yibing Yan, Martin Lauss, Göran B. Jönsson, Julia Newton-Bishop, Christine Parkinson, Mark R. Middleton, D. Timothy Bishop, Sarah McDonald, Nikki Stefanos, John Tadross, Ismael A. Vergara, Serigne Lo, Felicity Newell, James S. Wilmott, John F. Thompson, Georgina V. Long, Richard A. Scolyer, Pippa Corrie, David J. Adams, Alvis Brazma, Roy Rabbie

Get full text

Distinct immune cell infiltration patterns in pancreatic ductal adenocarcinoma (PDAC) exhibit divergent immune cell selection and immunosuppressive mechanisms by Shivan Sivakumar, Ashwin Jainarayanan, Edward Arbe-Barnes, Piyush Kumar Sharma, Maire Ni Leathlobhair, Sakina Amin, David J. Reiss, Lara Heij, Samarth Hegde, Assaf Magen, Felicia Tucci, Bo Sun, Shihong Wu, Nithishwer Mouroug Anand, Hubert Slawinski, Santiago Revale, Isar Nassiri, Jonathon Webber, Gerard D. Hoeltzel, Adam E. Frampton, Georg Wiltberger, Ulf Neumann, Philip Charlton, Laura Spiers, Tim Elliott, Maria Wang, Suzana Couto, Thomas Lila, Pallavur V. Sivakumar, Alexander V. Ratushny, Mark R. Middleton, Dimitra Peppa, Benjamin Fairfax, Miriam Merad, Michael L. Dustin, Enas Abu-Shah, Rachael Bashford-Rogers

Get full text